The role of the clinical and psychological symptoms of mastocytosis in the patient’s quality of life

Natalia Spolak-Bobryk, Marek Niedoszytko, Ewa Jassem, Marta Chelmińska, Magdalena Lange, Mikołaj Majkowicz, Bogusława Niedoszytko, Judyta Borchet

Department of Allergology, Medical University of Gdańsk, Gdańsk, Poland
Department and Clinic of Dermatology, Venereology and Allergology, Medical University of Gdańsk, Gdańsk, Poland
Faculty of Health Sciences, Pomeranian University, Ślupsk, Poland
Division of Research on Family and Quality of Life, Institute of Psychology, University of Gdańsk, Gdańsk, Poland

Abstract

Introduction: Patients with mastocytosis have various clinical and psychological symptoms, for example, life-threatening anaphylactic reactions or anxiety, resulting in decreased quality of life (QoL).

Aim: To assess the clinical and psychological symptoms (such as depression, anxiety) as well as the quality of life and satisfaction with life in patients with mastocytosis.

Material and methods: The study group included 85 patients with mastocytosis (57 women and 28 men) treated at the Department of Allergology, Medical University of Gdańsk, Poland. The measures employed in the study were the following: HADS-M, QLMS, and Cantril ladder.

Results: Among clinical symptoms that occurred in the studied group, only allergy differentiated between the patients in terms of their QoL. Patients experiencing allergy symptoms presented lower QoL in the area of leisure time. The study findings indicate that 27.1% of participants experience anxiety, 12.9% experience depression, 15.3% present low satisfaction with the current life, and 10.6% express low satisfaction with life in the next 4 weeks.

General QoL in mastocytosis, as well as the four areas of QoL in mastocytosis, remain positively correlated with anxiety, depression, and irritability, as well as negatively correlated with the satisfaction with current life and life in 4 weeks’ time.

Conclusions: Patients who experience allergy symptoms have a lower level of QoL in the area of leisure time. Having more obstacles in various areas of life is associated with anxiety, depression, irritability, and low satisfaction with life. Learning how to overcome them can potentially improve the patients’ QoL.

Key words: mastocytosis, quality of life, clinical symptoms, psychological symptoms.

Introduction

Mastocytosis is a rare heterogeneous neoplastic disease characterized by excessive, pathological accumulation of mast cells in one or more organs and release of their mediators. The disease is estimated to occur in approximately 10 per 100,000 people and is classified as a haematological neoplasm [1–3]. Mastocytosis has a wide spectrum of clinical manifestations: when the pathological accumulation of mast cells is limited only to the skin, the cutaneous mastocytosis (CM) is diagnosed, whereas when the accumulation of mast cells occurs in internal organs (most commonly the skin, bone marrow, gastrointestinal tract, spleen, liver and lymph nodes), the systemic mastocytosis (SM) is diagnosed. The clinical spectrum of mastocytosis also includes rare, unifocal mast cell tumours such as mast cell sarcoma, a poorly differentiated neoplasm that grows with the destruction of the surrounding tissue. The World Health Organisation (WHO) classification of the clinical forms of mastocytosis is shown in Figure 1 [4, 5].

The cutaneous form of mastocytosis appears in early childhood. It is manifested by urticaria pigmentosa (reddish-brown skin lesions), but the occurrence of Darier’s sign is also possible (nodules, papules or blisters, which cause redness and swelling when stroked), which is...
caused by the mediators contained in the inflammatory granules released by the mast cells.

In the systemic form of mastocytosis, mast cells usually accumulate in the bone marrow, spleen, liver, gastrointestinal tract, and lymph nodes. The infiltration of tissues by mast cells carries the risk of organ dysfunction and eventually the occurrence of significant disorders, such as impairment of the bone marrow function, liver failure, or osteoporotic fractures. The most common mediator-dependent symptoms include abdominal pain, fainting, diarrhoea, flushing (paroxysmal erythema), tachycardia, skin pruritus, dizziness and headache, nausea, fatigue, hypotonia, hypotension, and anaphylactic shock.

Mastocytosis can also be asymptomatic, but the dysfunction of the organism can be diagnosed on the basis of abnormalities in peripheral blood cell count, i.e., anaemia (too few erythrocytes), thrombocytopenia (decreased platelet count) or leukaemia (too few white blood cells) [3, 5–9]. Mastocytosis, both cutaneous and systemic, is associated with a risk of anaphylactic reaction. It occurs in about 50% of adults and about 5–10% of children with mastocytosis. In adults, it is usually related to an allergy to Hymenoptera venom, and in most children, it is provoked by an unknown factor [6]. Importantly, systemic mastocytosis is often accompanied by skin involvement, with typical skin lesions occurring in about 80% of all patients with mastocytosis.

Diagnosis of mastocytosis is based on histopathological examination of the skin and bone marrow, determination of serum tryptase levels, bone marrow cytology, immunophenotyping and detection of D816V mutation in the KIT gene. The main aim of the treatment of patients with indolent systemic and cutaneous mastocytosis is to prevent or reduce the severity of symptoms. The treatment is primarily based on patient education, the recommendation to avoid agents that provoke mast cell degranulation, the alleviation of acute and chronic mediator-related symptoms with antihistamine drugs blocking H1 and H2 receptor, cromones, leukotriene receptor antagonists, oral steroids, omalizumab, along with chemotherapy lesions in aggressive mastocytosis, and bone marrow transplantation in the most severe cases [5].

Patient education is closely linked to the information on factors that may lead to exacerbation of mastocytosis symptoms and anaphylactic reactions, such as exposure to sudden temperature changes, certain foods, additives or preservatives, pungent spices, some drugs, various allergens, sunlight, alcohol, venom (hymenopterous insects, jellyfish, snakes), latex, physical exertion, stress, bacterial and viral infections, mechanical irritation of skin lesions, fever or invasive diagnostic and therapeutic procedures. Mastocytosis patients or their caregivers should be trained in first aid in the event of an anaphylactic shock [1, 10–13].

### Figure 1. Classification of mastocytosis: current status and outlook toward the future (Valent et al. Cancer Res 2017)

The variety of forms of mastocytosis poses a significant problem as it impairs the diagnosis and treatment. This can cause further psychological problems, such as confusion, helplessness, and a sense of threat [14]. As many as 73% of patients experience anxiety due to the disease. Its principal causes include a long time to diagnosis (a mean of nearly 7 years), variety of forms, uncontrollable symptoms, inability to lead an active professional and social life (sense of exclusion, isolation, feeling useless), pain, chronic fatigue, disfigurement (skin lesions), fear of biopsy and chemotherapy [15, 16]. The anxiety experienced by patients may be associated with the sense of threat (unfavourable prognosis, threat to life), with symptoms (nausea, vomiting), and with the diagnostic and therapeutic procedures (radiotherapy, chemotherapy, biopsy). The increased anxiety is a result of disturbed cognitive functions (memory disorders, inability to concentrate), and disability (loss of autonomy and/or dependence on other people) [17].

### Aim

The aim of the study was to assess the clinical and psychological symptoms (such as depression, anxiety) as well as the quality of life and satisfaction with life in patients with mastocytosis.

### Material and methods

Eighty five patients participated in the study (57 women and 28 men) aged from 18 to 77 (Mtotal = 46.22, SDtotal = 13.10; Mmen = 43.32, SDmen = 10.80, Mwomen = 46.67, SDwomen = 14.16; Z = –0.64, p < 0.05). All of them had mastocytosis and were treated at the Department of Allergology, Medical University of Gdansk (Poland). The participants were diversified by their educational status, with higher education being the most prevalent (55.3%). Other participants had either secondary (27.1%), vocational (12.9%), or primary education (4.7%). The participants’ relationship status was as follows: married (75.3%), single (18.9%), widowed...
Natalia Spolak-Bobryk, Marek Niedoszytko, Ewa Jassem, Marta Chełmińska, Magdalena Lange, Mikołaj Majkowicz, Bogusław Niedoszytko, Judyta Borchet

(3.5%), and divorced (2.4%). Most of the participants were employed (71.8%). Some of them were retired or receiving a pension (18.9%), while 9.4% were unemployed.

The study received approval from the Independent Bioethics Committee for Scientific Research at the Medical University of Gdansk (NKBBN/550/2015). Participation in the study was voluntary and anonymous. The patients were invited to join the study by psychologists while they were visiting the clinic. None of them denied the request. All participants signed informed consent prior to joining the study. The study protocol lasted approximately 30 to 40 min. The data collection started in 2015 and was completed in 2019.

Using the psychological tools listed below, the level of anxiety and depression, as well as the level of satisfaction and quality of life were analysed in the study participants.

The following questionnaires were used: HADS-M, Cantril Ladder, and Quality of Life in Mastocytosis Scale (QLMS).

Hospital Anxiety and Depression Scale – Modified Version (HADS-M) was created by Zigmond and Snaith. The version employed in this study was adapted for use in Poland by Majkowicz, de Walden-Gałuszko and Chojnacka-Szawłowska [18]. HADS-M includes three subscales: depression (HADS-D), anxiety (HADS-A), and irritability. The scale allows assessing the presence of these symptoms in patients hospitalized due to somatic causes. The scale includes 16 statements, assessed on a 4-point scale (i.e., 1 = definitely yes, 2 = rather yes, 3 = rather no, 4 = definitely no). The possible scores range from 0 to 21 points. Scores from 0 to 7 are considered normal, from 8 to 10 are borderline, those above 11 signify a high level of anxiety and/or depression in the setting of a hospital outpatient clinic [19].

Cantril Ladder is a visual measure of life satisfaction. It is presented in the form of a ladder, whose steps are marked with consecutive numbers from 0 to 10. The top step, numbered 10, means the best possible life, while the bottom step, numbered 0, implies the worst possible life. The respondent evaluates his or her life (1) at the current moment and (2) predicts his or her satisfaction with life in the next 4 weeks by marking the right step of the ladder [20]. Scores lower than 6 indicate people unsatisfied with their lives while scores above 6 are considered as an indicator of being satisfied with one’s life.

Quality of Life in Mastocytosis Scale (QLMS) is a mastocytosis-specific quality of life measure. It assesses the quality of patients’ lives in four domains such as leisure time, protective behaviours, professional life, and life limitations. The scale includes 24 items with a score ranging from 0 (there are no limitations in a given area) to 5 points (the limitation prevents normal functioning). Raw scores are summed and then divided by the number of items on each subscale. The higher the score in a given subscale, the more difficulties the patient experiences in that area of life. The scale also provides a total score expressed as the mean score of all the items [21].

Statistical analysis

The analyses were performed using IBM SPSS Statistics 23. Data on continuous variables (i.e., age, Cantril ladder scores, HADS-M, and QLMS subscales’ scores) were presented as means and standard derivations (SD) (Table 1). To test whether gender or mastocytosis type differentiate between the patients in terms of their subscales’ scores, and taking into consideration that the groups were unequal, the non-parametric U Mann-Whitney tests were performed [22, 23]. The results are presented in Tables 2 and 3, respectively, alongside with medians and quartiles. Values of $p < 0.05$ were considered statistically significant. As all of the differences were non-significant, gender was not included in further analysis. Moreover, the mastocytosis type (i.e., cutaneous or systemic) did not significantly differ between the patients in terms of their general quality of life and its domains as measured by QLMS (Table 3).

| Table 1. General descriptive statistics ($N = 85$) |
|-------|-------|-------|-------|
| Variable | Min. | Max. | Mean | SD |
| Age | 18 | 77 | 46.22 | 13.10 |
| HADS-M Anxiety | 0.0 | 17.0 | 5.47 | 4.06 |
| HADS-M Depression | 0.0 | 9.0 | 2.99 | 2.94 |
| HADS-M Irritability | 0 | 6 | 2.59 | 1.58 |
| Cantril – today | 7.39 | 15.9 | 3.0 | 10.0 |
| Cantril – next 4 weeks | 7.80 | 15.1 | 4.0 | 10.0 |
| QLMS – leisure time | 0.00 | 4.44 | 0.55 | 0.77 |
| QLMS – protective behaviours | 0.00 | 4.33 | 0.51 | 0.76 |
| QLMS – professional life | 0.00 | 4.75 | 0.62 | 0.98 |
| QLMS – life limitations | 0.00 | 5.00 | 0.89 | 1.07 |
| QLMS – global quality of life in mastocytosis | 0.00 | 4.63 | 0.64 | 0.80 |
Results

There were 85 mastocytosis patients participating in the study (57 women and 28 men), treated at the Department of Allergology, Medical University of Gdansk, Gdansk, Poland. The descriptive data regarding the participant’s gender, age, and mastocytosis type are presented in Table 4 below. The frequencies of clinical symptoms occurrence in the studied group are presented in Table 5 below. None of the patients was found to experience malabsorption, portal hypertension, ascites, dysmyelopoiesis, and lymphadenopathy. 81.2% (n = 69) of the participants did not provide any information on the occurrence of hypotension so this parameter was not analysed further. Also, the results of ANOVAs indicated that flushing and pruritus did not differentiate between the patients in terms of their quality of life or its domains (p > 0.05) and the level of tryptase was not correlated with the general quality of life in mastocytosis or with its four domains (p > 0.05).

The differences in the quality of life and its 4 domains (leisure time, protective behaviours, professional life, and life limitations) for two independent groups of patients with or without clinical symptoms such as: allergy, GI tract symptoms, osteopenia/osteoporosis symptoms, constitutional/cardiovascular symptoms, weight loss, and hepatomegaly, are presented in Table 6 below. Surprisingly, the occurrence of those symptoms did not affect the patients’ quality of life, with only one exception. Patients who experienced allergy symptoms experienced more dissatisfaction with their leisure time than those who did not suffer from allergy symptoms.

The study findings indicate that 27.1% of study participants experienced anxiety, and 12.9% demonstrated signs of depression (i.e., HADS subscales scored higher than 7). Therefore, anxiety was more prevalent than depression. Low satisfaction with the current life was experienced by 15.3% of the patients and the satisfaction with life in the next 4 weeks was assessed as low by 10.6% of study participants (i.e., scores on Cantril ladder lower than 6). None of the patients presented borderline or high levels of irritability.

The effect sizes varied from low to moderate (rho coefficients ranging from 0.23 to 0.47). Global quality of life in mastocytosis was moderately positively correlated with anxiety (rho = 0.44; p < 0.01), depression (rho = 0.35; p < 0.01), and irritability (rho = 0.34; p < 0.01) as

---

**Table 2.** Gender differences in questionnaires’ results

| Variable                   | Mean rank – men | Quartiles – men | Mean rank – women | Quartiles – women | U-Mann Whitney test of group differences |
|----------------------------|-----------------|-----------------|-------------------|-------------------|-----------------------------------------|
| HADS-M Anxiety             | 37.14           | 1.00            | 4.00              | 7.75              | 45.88                                   | 3.00 | 4.00 | 9.00 | -1.54; n.s. |
| HADS-M Depression          | 46.66           | 0.25            | 2.50              | 6.50              | 41.20                                   | 0.00 | 2.00 | 5.00 | 0.97; n.s.   |
| HADS-M Irritability        | 40.36           | 1.25            | 2.50              | 3.00              | 44.30                                   | 1.50 | 3.00 | 4.00 | -0.71; n.s. |
| Cantril – today            | 45.63           | 7.00            | 8.00              | 8.00              | 41.71                                   | 6.00 | 8.00 | 8.00 | -0.71; n.s. |
| Cantril – next 4 weeks     | 38.88           | 7.00            | 8.00              | 8.00              | 45.03                                   | 7.00 | 8.00 | 9.00 | -1.11; n.s. |
| QLMS – leisure time        | 39.27           | 0.00            | 0.17              | 0.92              | 45.19                                   | 0.00 | 0.33 | 0.83 | -1.01; n.s. |
| QLMS – protective behaviours| 38.54           | 0.00            | 0.00              | 0.67              | 45.19                                   | 0.00 | 0.33 | 0.83 | -1.24; n.s. |
| QLMS – professional life   | 43.57           | 0.00            | 0.38              | 0.94              | 42.72                                   | 0.00 | 0.00 | 1.00 | -0.16; n.s. |
| QLMS – life limitations    | 39.96           | 0.00            | 0.50              | 1.15              | 44.49                                   | 0.00 | 0.60 | 1.30 | -0.81; n.s. |
| QLMS – global quality of life in mastocytosis | 40.14 | 0.01 | 0.44 | 0.78 | 44.40 | 0.18 | 0.39 | 0.99 | -0.75; n.s. |

**Table 3.** Quality of life in cutaneous and systemic mastocytosis patients (n = 85)

| Variable                   | Cutaneous mastocytosis (n = 19) | Systemic mastocytosis (n = 66) | U-Mann Whitney test of group differences |
|----------------------------|---------------------------------|---------------------------------|-----------------------------------------|
| QLMS – leisure time        | 47.97                           | 0.00                            | 0.44                                   | 1.11                                   | 45.17                                   | 0.00 | 0.28 | 0.78 | -1.03; n.s. |
| QLMS – protective behaviours| 44.03                           | 0.00                            | 0.33                                   | 0.67                                   | 42.70                                   | 0.00 | 0.08 | 0.83 | -0.22; n.s. |
| QLMS – professional life   | 39.37                           | 0.00                            | 0.00                                   | 0.50                                   | 44.05                                   | 0.00 | 0.25 | 1.00 | -0.78; n.s. |
| QLMS – life limitations    | 46.42                           | 0.40                            | 0.60                                   | 1.20                                   | 42.02                                   | 0.00 | 0.60 | 1.20 | -0.70; n.s. |
| QLMS – global quality of life in mastocytosis | 45.50 | 0.26 | 0.52 | 0.84 | 42.28 | 0.07 | 0.38 | 0.85 | -0.50; n.s. |
The analysis of rho-Spearman correlation between the studied variables and the 4 areas of the quality of life in mastocytosis revealed that (1) the more limitations in leisure time the participants encountered, the more anxiety (rho = 0.46; p < 0.01), depression (rho = 0.31; p < 0.01), and irritability (rho = 0.33; p < 0.01) as well as the less satisfaction with the current life (rho = –0.31; p < 0.01) and life in the next 4 weeks they experienced (rho = –0.35; p < 0.01); (2) the more limitations related to protective behaviours the participants encountered in their lives, the more anxiety (rho = 0.23; p < 0.05) and the less satisfaction with the current life (rho = –0.34; p < 0.01) and life in the next 4 weeks they experienced (rho = –0.36; p < 0.01) they experienced; (2) the more limitations related to protective behaviours the participants encountered in their lives, the more anxiety (rho = 0.23; p < 0.05) and the less satisfaction with the current life (rho = –0.34; p < 0.01) and life in the next 4 weeks they experienced (rho = –0.36; p < 0.01); (3) the more limitations in professional life the participants encountered, the more anxiety (rho = 0.41; p < 0.01), depression (rho = 0.31; p < 0.01), and irritability (rho = 0.33; p < 0.01) as well as the less satisfaction with the current life (rho = –0.31; p < 0.01) and life in the next 4 weeks they experienced (rho = –0.35; p < 0.01); (4) the more limitations in everyday life the participants encountered, the more anxiety (rho = 0.47; p < 0.01), depression (rho = 0.39; p < 0.01), and irritability (rho = 0.33; p < 0.01) as well as the less satisfaction with the current life (rho = –0.31; p < 0.01) and life in the next 4 weeks they experienced (rho = –0.33; p < 0.01).

Participants’ age was not related to either the QLMS’ global quality of life in mastocytosis score or to its subscales. The correlations between the psychological variables, age, and QLMS scores are presented in Table 7.

**Table 4. Patient characteristics by gender**

| Parameter                        | Men          | Women         |
|----------------------------------|--------------|---------------|
| N (%)                            | 28 (33)      | 57 (67)       |
| Age                              | M = 45.32; SD = 10.80 | M = 46.67; SD = 14.16 |
| Diagnosis of mastocytosis        | Cutaneous mastocytosis (CM) 19 (22.4%) | Systemic mastocytosis (SM) 66 (77.6%) |
| Diagnosis of mastocytosis by gender | Women 14 (24.6%) | Women 43 (75.4%) |
|                                  | Men 5 (17.9%) | Men 23 (82.1%) |

**Table 5. Frequency of clinical symptoms in the study group (n = 85)**

| Symptom                                  | No symptoms | Mild & infrequent | Mild or moderate & frequent | Severe & frequent | Severe adverse event | No data |
|------------------------------------------|-------------|-------------------|-----------------------------|-------------------|----------------------|---------|
| Allergy                                  | 44          | 36                | 5                           |                   |                      |         |
| G1 tract symptoms                        | 25          | 56                | 4                           |                   |                      |         |
| Osteopenia/osteoporosis (symptoms)       | 19          | 48                | 18                          |                   |                      |         |
| Constitutional/cardiovascular           | 16          | 67                | 2                           |                   |                      |         |
| Weight loss (≥10% within last 12 months) | 3           | 82                | 0                           |                   |                      |         |
| Malabsorption                            | 0           | 84                | 1                           |                   |                      |         |
| Portal hypertension                      | 0           | 85                | 0                           |                   |                      |         |
| Ascites                                  | 0           | 85                | 0                           |                   |                      |         |
| Dysmyelopoiesis                          | 0           | 85                | 0                           |                   |                      |         |
| Spleen (palpable)                        | 1           | 83                | 1                           |                   |                      |         |
| Hepatomegaly (palpable)                  | 3           | 81                | 1                           |                   |                      |         |
| Lymphadenopathy (palpable or > 2 cm in US/CT) | 0           | 84                | 1                           |                   |                      |         |
| Hypotension                              | 1           | 7                 | 6                           | 1                 | 1                    | 69      |
| Flushing                                 | 15          | 19                | 30                          | 4                 | 0                    | 17      |
| Pruritus                                 | 7           | 18                | 40                          | 3                 | 0                    | 17      |

Discussion

The results of our study indicated the importance of allergic symptoms and limitations in leisure time, which decrease quality of life. Firstly, among the clinical symptoms that oc-
The role of the clinical and psychological symptoms of mastocytosis in the patient’s quality of life

curred in the studied group, which were allergy, GI tract symptoms, osteopenia/osteoporosis symptoms, constitutional/cardiovascular symptoms, weight loss, and hepatomegaly, only symptoms of allergy analysed by our questionnaire differentiated between the patients in terms of their quality of life, and it was in the area of leisure time. Patients experiencing allergy symptoms presented lower QoL in the area of leisure time. This symptom prevents them from, for instance, going on holiday, traveling, visiting friends and family, and enjoying themselves outdoors (e.g., when walking or gardening).

A possible reason for the anxiety reported by the studied patients could be the fear of experiencing allergic symptoms in a place where professional medical assistance was not available. For example, if an anaphy-

| Table 6. The differences in QLMS dimensions by clinical symptoms occurrence |
|---------------------------------|----------------|----------------|
| Symptom                        | Mean rank – symptom present | Mean rank – symptom not present | U-Mann Whitney test of group differences |
| QLMS – leisure time:            |                 |                |
| Allergy                         | 45.73           | 34.11          | −2.29; p < 0.05 |
| GI tract symptoms               | 39.00           | 41.89          | −0.52; n.s.    |
| Osteopenia/osteoporosis (symptoms) | 34.34        | 33.86          | −0.09; n.s.    |
| Constitutional/cardiovascular  | 47.69           | 40.64          | −1.08; n.s.    |
| Weight loss (≥ 10% within last 12 months) | 38.17   | 43.18          | −0.36; n.s.    |
| Hepatomegaly (palpable)         | 62.33           | 41.77          | −1.48; n.s.    |
| QLMS – protective behaviours:   |                 |                |
| Allergy                         | 44.56           | 35.54          | −1.81; n.s.    |
| GI tract symptoms               | 38.38           | 42.17          | −0.71; n.s.    |
| Osteopenia/osteoporosis (symptoms) | 33.63        | 34.15          | −0.10; n.s.    |
| Constitutional/cardiovascular  | 41.63           | 42.09          | −0.07; n.s.    |
| Weight loss (≥ 10% within last 12 months) | 38.67   | 43.16          | −0.33; n.s.    |
| Hepatomegaly (palpable)         | 37.17           | 42.70          | −0.41; n.s.    |
| QLMS – professional life:       |                 |                |
| Allergy                         | 41.74           | 38.99          | −0.56; n.s.    |
| GI tract symptoms               | 40.04           | 41.43          | −0.26; n.s.    |
| Osteopenia/osteoporosis (symptoms) | 32.97        | 34.41          | −0.29; n.s.    |
| Constitutional/cardiovascular  | 38.38           | 42.87          | −0.72; n.s.    |
| Weight loss (≥ 10% within last 12 months) | 51.67   | 42.68          | −0.66; n.s.    |
| Hepatomegaly (palpable)         | 48.00           | 42.30          | −0.43; n.s.    |
| QLMS – life limitations:        |                 |                |
| Allergy                         | 41.24           | 39.60          | −0.32; n.s.    |
| GI tract symptoms               | 41.96           | 40.57          | −0.25; n.s.    |
| Osteopenia/osteoporosis (symptoms) | 34.24        | 33.91          | −0.06; n.s.    |
| Constitutional/cardiovascular  | 41.13           | 42.21          | −0.16; n.s.    |
| Weight loss (≥ 10% within last 12 months) | 41.83   | 43.04          | −0.09; n.s.    |
| Hepatomegaly (palpable)         | 42.33           | 42.51          | −0.01; n.s.    |
| QLMS – Global quality of life in mastocytosis: | | |
| Allergy                         | 43.39           | 36.97          | −1.23; n.s.    |
| GI tract symptoms               | 40.68           | 41.14          | −0.08; n.s.    |
| Osteopenia/osteoporosis (symptoms) | 34.03        | 33.99          | −0.01; n.s.    |
| Constitutional/cardiovascular  | 42.22           | 41.95          | −0.04; n.s.    |
| Weight loss (≥ 10% within last 12 months) | 41.83   | 43.04          | −0.30; n.s.    |
| Hepatomegaly (palpable)         | 50.33           | 42.21          | −0.57; n.s.    |
Anxiety is a common emotional state, a natural reaction to diseases, and a consequence of the sense of threat. In the studied group of patients with mastocytosis, anxiety was observed in 27.1% of the subjects. Additionally, signs of depression were found in 12.9% of the patients. Thus, in the studied population, anxiety was more prevalent than depression. The assessment was performed using the HADS-M questionnaire, a measure of anxiety and depression.
The role of the clinical and psychological symptoms of mastocytosis in the patient’s quality of life

The dissatisfaction with current life was assessed by 15.3% of patients with mastocytosis. 10.6% assessed their satisfaction with their lives in the next 4 weeks as low. This assessment was based on the scores of the Cantril Ladder, a measure successfully used in studying patients with various conditions. For example, Sułkowski et al. used it in a study on satisfaction with life in patients undergoing dialysis. The results indicated highly positive relationships between high expected 5-year Cantril Ladder-satisfaction with life scores and being in a relationship, having a kidney graft performed in the past, and willingness to have a kidney graft performed in the future [37]. The Cantril Ladder was also used in a study by Cepuch. Its aim was to assess the degree of pain and the level of activity and disease acceptance in a group of 50 subjects, aged 14–18 years, with juvenile idiopathic arthritis (JIA) in remission. Apart from Cantril Ladder, this study used the numerical scale (NRS 0 – 10), the author’s own activity scale, and the Acceptance of Illness Scale (AIS). A high correlation was observed between the acceptance of the disease determined with the use of Cantril Ladder and AIS at the moment of the test [38].

General QoL in mastocytosis, as well as the four areas of QoL in mastocytosis (leisure time, protective behaviours, professional life, and life limitations), generally remained moderately positively correlated with anxiety, depression, and irritability as well as negatively correlated with satisfaction with current life and life in the next 4 weeks. The obtained results are consistent with the investigations by Urbańska, who emphasizes the importance of daily life in the ecosystem when the reality in which a person functions forces them to be active in constantly changing conditions. The sense of obligation to meet expectations and fulfill tasks related to one’s social position, including family, everyday life, health, and work functions, has a profound impact on the occurrence of psychophysical imbalance and may result in intense fatigue, both psychological (lack of security, autonomy, unmet needs), physical (lack of rest) and social (overload with interactions), which, in turn, is linked to anxiety, depression, irritability, and low satisfaction with life [39].

As our study was correlational, we cannot infer the causality in these relations. However, we know that the anxiety experienced by mastocytosis patients may be associated with the sense of threat to life, suffering from the disease symptoms, and undergoing diagnostic and therapeutic procedures [17]. Therefore, we believe that educating the patients on their condition and the factors that may lead to the exacerbation of mastocytosis symptoms (e.g., exposure to sudden temperature changes, certain foods, pungent spices, certain medications, sunlight, alcohol, insect venoms, stress, or infections) could increase their sense of safety and decrease the anxiety and thus have a positive impact on their quality of life. This idea seems to be in line with the fact that in our sample, the levels of depression and irritability did not remain statistically significantly correlated with the level of protective behaviours the patients undertake. It is possible that the study participants knew the benefits of protective actions thus were not irritated or depressed because of them. Having more obstacles in various areas of life (work, leisure time, everyday life, and the need to perform many protective behaviours) is linked to anxiety, depression, irritability, and low satisfaction with life. Learning how to overcome them can potentially improve the patients’ quality of life.

Acknowledgments

This work is a result of collaboration between the patients of the Department of Allergology, Medical University of Gdansk, Poland, and the medical personnel – psychologists and physicians. We would like to recognize their participation.

The study was supported by one of the authors’ scholarship – Natalia Spolak-Bobryk was awarded with a Santander Universidades Scholarship (29/2020).

Conflict of interest

The authors declare no conflict of interest.

References

1. Le M, Miedzybrodzki B, Olynch T, et al. Natural history and treatment of cutaneous and systemic mastocytosis. Postgraduate Medicine 2017; 129: 896-901.
2. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am 2014; 34: 283-95.
3. Valent P, Akin C, Hartmann K, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res 2017; 77: 1261-70.
4. Valent P, Akin C, Metcalfe D.D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420-7.
5. Lange M, Flisiak I, Kapinańska-Mrowiecka ML, et al. Mastocytosis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Dermatol Rev 2018; 105: 358-83.
6. Hartmann K, Escobaro L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and
24. Maser B, Weiermair K. Travel decision-making: from the vintage point of perceived risk and information preferences. J Travel Tourism Marketing 1998; 7: 107-21.
25. Roehl W, Fesenmaier D. Risk perceptions and pleasure travel: an exploratory analysis. J Travel Res 1992; 30: 17-26.
26. Matysiak J, Matysiak J, Kokot ZJ, et al. Alergia na jad owadów błonkoskrzydłych ze szczególnym uwzględnieniem pszczoły miodnej (Apis mellifera) – aktualny stan wiedzy. Alergia Astma Immunol 2011; 16: 163-71.
27. Bonifazi F, Jetel M, Bilo B, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60: 1459-70.
28. Bilo B, Rueff F, Mosbech H, et al. Diagnosis of Hymenoptera venom allergy. Allergy 2005; 60: 1339-49.
29. Oude Elberink J, de Monchy J, Golden D, et al. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol 2002; 109: 162-70.
30. Oude Elberink J, de Monchy J, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110: 174-82.
31. Niedoszytko M, Majkowicz M, Chełmińska M, et al. Quality of life, anxiety, depression and satisfaction with life in patients treated with insect venom immunotherapy. Adv Dermatol Allergol 2012; 29: 74-9.
32. Greene A, Breisch NL. Avoidance of bee and wasp stings: an entomological perspective. Curr Opin Allergy Clin Immunol 2005; 5: 337-41.
33. American Academy of Allergy, Asthma, and Immunology, Public Education Committee. Tips to remember. Available online: https://ohioallergyclinic.com/wp-content/uploads/pdfs/Patients&Consumers_Center_%20Tips_to_Remember_Outdoor_allergens.pdf
34. Lin CY, Pakpour AH. Using Hospital Anxiety and Depression Scale (HADS) on patients with epilepsy: confirmatory factor analysis and Rasch models. Seizure 2017; 45: 42-6.
35. Wichowicz HM, Wieczorek D. Badanie przesiewowe depresji poudarowej z użyciem Hospital Anxiety Depression Scale (HADS). [Screening for post-stroke depression with the use of Hospital Anxiety Depression Scale (HADS)]. Psychiatr Pol 2011; 36: 505-14.
36. Sułkowski L, Matyja M, Walocha JA, et al. Satisfaction with life among dialyzed patients: a cantril ladder survey. MGM J Med Sci 2018; 5: 6-11.
37. Cepuch G, Tomaszek L, Trybek-Bronowicz M. Pain intensity in patients with juvenile idiopathic arthritis and the level of their activity and the disease acceptance. Reumatologia 2014; 52: 299-304.
38. Urbańska J. Zmęczenie życiem codziennym. Środowiskowe Psychologii Społecznych Uniwersytetu im. Adama Mickiewicza. Poznań, Polska 2010.